On August 31, 2026 BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reported a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne’s longstanding commitment to patient access and investment in research and scientific innovation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said:
"At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide."

Improved access to oncology medicines for patients
This announcement reflects BeOne’s participation in the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model and the company’s commitment to pricing future FDA-approved products in line with other key developed markets.

Increased manufacturing and investment
Through continued investments in U.S. manufacturing, BeOne is enhancing supply continuity and manufacturing flexibility while supporting patient access to innovative medicines.

BeOne entered into an onshoring agreement with the U.S. government, securing an exemption from Section 232 pharmaceutical tariffs that recognizes the company’s significant and ongoing investments in US. manufacturing.
The company recently announced a $300 million onshoring investment in its flagship clinical and commercial-stage manufacturing and research and development facility in Hopewell, NJ, bringing total U.S. manufacturing investment to more than $1 billion. The expansion will add small-molecule manufacturing capacity, create approximately 120 full-time jobs and enhance BeOne’s ability to manufacture medicines in the states and advance its oncology pipeline of more than 35 clinical- and commercial-stage assets.
The U.S. is an important hub for BeOne’s scientific, clinical and manufacturing operations. BeOne employs more than 2,000 U.S. colleagues within a global team of more than 12,000 across six continents. In 2025, the company generated nearly $2 billion in direct U.S. economic impact and invested $1 billion in U.S. research and development. BeOne is also advancing one of oncology’s broadest pipelines through 93 clinical trials at approximately 1,100 sites across 45 states and one territory, supported by more than 650 investigators.

(Press release, BeOne Medicines, AUG 31, 2026, View Source [SID1234670471])

On August 31, 2026 BostonGene, developer of the leading AI model for tumor and immune biology, reported that two abstracts have been accepted for poster presentation at Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, taking place September 9 – 12 in Houston, Texas. The 14th Annual Meeting will bring together thousands of global experts to showcase practice-changing breakthroughs and practical clinical applications in blood cancer treatment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At SOHO 2026, BostonGene will highlight advanced molecular stratification frameworks designed to unlock actionable insights from complex multimodal datasets. These studies provide biopharma partners with robust translational tools to optimize patient selection, guide treatment sequencing, and accelerate precision oncology pipelines across B-cell lymphomas and multiple myeloma.

Details about the abstracts selected for presentation can be found below:

Poster presentations
Poster number: MM-442
Title: An Actionability Score for BCMA-, GPRC5D-, and CD38-targeted therapy selection in multiple myeloma
Date & time: Wednesday, September 9 | 6:25 – 7:55 PM EDT
Location: Hall B3, Level 3 – George R. Brown Convention Center
Speaker: Tamara Laskowski, PhD, BostonGene

BostonGene introduced an NGS-based Actionability Score (AS) framework that integrates target gene expression, resistance factors, and tumor microenvironment signatures to predict response and guide treatment selection across key immunotherapies targets (BCMA, GPRC5D, and CD38) in multiple myeloma. Applied across multiple myeloma cohorts, the AS framework identified distinct actionable profiles and potential resistance mechanisms, offering biopharma a predictive tool to refine clinical trial design and optimize treatment sequencing.

Poster number: ABCL-443
Title: Cross-disease stratification by genetic classifier Lymphly reveals shared molecular programs across B-cell malignancies
Date & time: Wednesday, September 9 | 6:25 – 7:55 PM EDT
Location: Hall B3, Level 3 – George R. Brown Convention Center
Speaker: Mark Meerson, MSc, BostonGene

BostonGene evaluated its interpretable, rule-based genetic classifier, Lymphly, across more than 6,500 DLBCL and non-DLBCL B-cell lymphoma samples. The study demonstrates that Lymphly uncovers shared molecular biology across diverse B-cell diagnoses, maintains superior subtype assignment preservation compared to legacy classifiers even with limited targeted panel data, and retains independent prognostic value, establishing a robust framework for cross-disease stratification and biomarker-driven trial design.

(Press release, BostonGene, AUG 31, 2026, View Source [SID1234670470])

On August 31, 2026 PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446) reported the U.S. Food and Drug Administration (FDA) has approved BESREMi (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET), making it the first new FDA-approved treatment for ET in nearly three decades. BESREMi has been approved for adults with ET, regardless of their genotype or disease status, including newly diagnosed patients who are naive to cytoreductive therapy. The ET approval expands the BESREMi product label, which has been commercially available for the treatment of adults with polycythemia vera (PV).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This approval marks a major milestone for people living with ET, a rare chronic blood cancer characterized by an overproduction of platelets. Patients with ET often require years of ongoing disease management and remain at risk for serious complications, such as heart attacks, strokes and pulmonary embolism.1 The approval of BESREMi provides a new ET treatment option and offers the potential for durable disease control, addressing a longstanding unmet need in ET care.

BESREMi is a long-acting interferon-based therapy designed to provide sustained disease management for ET. It offers a differentiated treatment option compared with current therapies that primarily focus on controlling platelet counts and symptoms, with limited impact on the underlying disease biology.2 Using novel monopegylation technology and an extended half-life, BESREMi is designed to target disease-driving cells in the bone marrow while reducing elevated platelet counts and disease burden.

"For nearly 30 years, people living with ET and the physicians treating them have had limited treatment innovation," said Ruben Mesa, M.D., principal investigator of the SURPASS-ET trial and President of Advocate Health’s Cancer National Service Line, which includes Atrium Health Levine Cancer Institute and the Comprehensive Cancer Center at Atrium Health Wake Forest Baptist. "In my experience, patients need treatment options that not only control blood counts but also address the underlying disease. The approval of BESREMi provides an important new treatment option that is supported by strong clinical evidence and that also works at the source of the disease rather than solely managing symptoms."

The FDA approval of BESREMi is based on clinical data demonstrating durable modified European Leukemia Net (ELN) responses and durable hematologic control in adults with ET. In the global Phase 3 SURPASS ET clinical trial (NCT04285086), BESREMi achieved superior durable response rates compared with anagrelide and reduced thromboembolic events over 12 months of treatment.

"Today’s FDA approval of BESREMi for ET is a significant advancement for patients and reflects PharmaEssentia’s longstanding commitment to advancing innovative therapies for people living with myeloproliferative neoplasms," said Ko-Chung Lin Ph.D., founder and CEO of PharmaEssentia. "We have been working closely with the FDA, healthcare providers, advocacy organizations and payers to bring this important treatment option to the ET community."

This announcement follows BESREMi’s recent regulatory approval in Japan and Taiwan for ET and further expands the company’s MPN portfolio. BESREMi for ET is expected to be available in the United States immediately upon approval. Additional information, including Prescribing Information, is available here.

(Press release, PharmaEssentia, AUG 31, 2026, View Source [SID1234670469])

On August 31, 2026 Vir Biotechnology, Inc. (Nasdaq: VIR), reported that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14 at 7:45 a.m. ET in New York City, New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available at View Source and will be archived for 30 days.

(Press release, Vir Biotechnology, AUG 31, 2026, View Source [SID1234670468])

On August 31, 2026 TriSalus Life Sciences Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, reported that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference. Management will participate in one-on-one meetings on Monday, September 14 and Tuesday, September 15, and will participate in a Fireside chat on Monday, September 14 at 5:00 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast replay of the Fireside chat will be available for 90 days following the Fireside chat in the Events section of the TriSalus Investor website at www.investors.trisaluslifesci.com.

(Press release, TriSalus Life Sciences, AUG 31, 2026, View Source [SID1234670467])